Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...

Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been “growing increasingly constructive for some time now.” The upgrade ...

BioNTech (NASDAQ:BNTX) stock rose 1.9% after Evercore ISI upgraded its stance on the drugmaker to ‘outperform’ from ‘in line’ ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and ...

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...